Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer

AR collaborates with ERα in aromatase inhibitor-resistant breast cancer

(2014) Yassine Rechoum et al.   BREAST CANCER RESEARCH AND TREATMENT

Abstract OT3-2-01: A phase 2 randomized, double-blind, placebo-controlled multicenter trial evaluating the efficacy and safety of enzalutamide in combination with exemestane in estrogen or progesterone receptor-positive and HER2 non-amplified advanced breast cancer

(2014) DA Yardley et al.   CANCER RESEARCH

Increased androgen receptor activity and cell proliferation in aromatase inhibitor-resistant breast carcinoma

(2014) Rika Fujii et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling

(2013) Susan Thrane et al.   BREAST CANCER RESEARCH AND TREATMENT

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

(2012) Howard I. Scher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Biological mechanisms and clinical implications of endocrine resistance in breast cancer

(2011) Mario Giuliano et al.   BREAST

Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal Women

(2011) R. Hu et al.   CLINICAL CANCER RESEARCH

Loss of Rho GDIα and Resistance to Tamoxifen via Effects on Estrogen Receptor α

(2011) Ines Barone et al.   JNCI-Journal of the National Cancer Institute

Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer

(2010) M. Cristofanilli et al.   CLINICAL CANCER RESEARCH

Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells

(2009) Francesca De Amicis et al.   BREAST CANCER RESEARCH AND TREATMENT

Androgen Receptor Inhibits Estrogen Receptor-  Activity and Is Prognostic in Breast Cancer

(2009) A. A. Peters et al.   CANCER RESEARCH

Short Preoperative Treatment With Erlotinib Inhibits Tumor Cell Proliferation in Hormone Receptor–Positive Breast Cancers

(2008) Marta Guix et al.   JOURNAL OF CLINICAL ONCOLOGY

Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors

(2008) Elisa J. Cops et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY